drugset / Trial / NCT04184453

Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients

NCT04184453

NaSingle-groupOpen-labelTreatment

Summary

Aceruloplasminemia is an autosomal recessive disorder characterized by iron deposition in the brain and visceral organs. Deferiprone was used to treat aceruloplasminemia in previous study. In this study, we will assess the clinical curative effect evaluation of oral deferiprone in Chinese aceruloplasminemia patients.

Timeline

Start
2019-12-23
Primary completion
2022-10-23
Completion
2022-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 25 mg/kg Oral

Indications